natgillin/translations-raw huggingface dataset:
No dosage adjustment of Copalia is required for patients with mild to moderate renal impairment (GFR &gt; 30 ml/min/1.73 m2).
Pri bolnikih z blago do zmerno okvaro ledvic (GFR &gt; 30 ml/min/1,73 m2) odmerka zdravila Copalia ni treba prilagajati.
No dosage adjustment of Exforge is required for patients with mild to moderate renal impairment (GFR &gt; 30 ml/min/1.73 m2).
Pri bolnikih z blago do zmerno okvaro ledvic (GFR &gt; 30 ml/min/1,73 m2) odmerka zdravila Exforge ni treba prilagajati.
No dosage reduction is required for patients with creatinine clearance &gt; 20 ml/min.
Pri bolnikih s kreatininskim očistkom 20 ml/min odmerka ni treba prilagajati.
No dosage reduction is required for patients with mild renal impairment (creatinine clearance &gt; 50 ml/min).
Bolnikom z blago okvaro ledvic (očistek kreatinina &gt; 50 ml/min) odmerka ni treba zmanjšati.
No dosage reduction is required for patients with mild renal impairment (creatinine clearance &gt; 50 ml/min).
Pri bolnikih z blago okvaro ledvic (kreatininski očistek &gt; 50 ml/min) odmerka ni treba prilagajati.
No dose adjustment for Empliciti is required for patients with mild hepatic impairment (total bilirubin [TB] ≤ to the upper limit of normal [ULN] and AST &gt; ULN or TB &lt; 1 to 1.5 × ULN and any AST).
Pri bolnikih z blago okvaro jeter (vrednost skupnega bilirubina [SB] ≤ od zgornje meje normalne [ZMN] vrednosti in vrednost AST &gt; od ZMN vrednosti ali vrednost SB &lt; od 1 do 1,5 × ZMN vrednosti in katera koli vrednost AST) odmerka zdravila Empliciti ni treba prilagajati.
No dose adjustment is necessary for patients with mild renal impairment (CLcr ≥50 and &lt; 80 mL/min).
Pri bolnikih z blago ledvično okvaro (CLcr ≥ 50 in &lt; 80 ml/min) prilagajanje odmerka ni potrebno.
No dose adjustment is necessary for patients with mild renal impairment (CLcr ≥50 and &lt; 80 mL/min).
Pri bolnikih z blago ledvično okvaro (CLcr ≥ 50 in &lt; 80 ml/min) prilagajanje odmerkov ni potrebno.
No dose adjustment is necessary in patients with impaired renal function (creatinine clearance &gt; 4 ml/min) (see section 5.2).
Bolnikom z okvarjenim delovanjem ledvic (očistek kreatinina &gt; 4 ml/min) odmerka ni treba prilagoditi (glejte poglavje 5.2).
No dose adjustment is necessary in patients with impaired renal function (creatinine clearance &gt; 4 ml/min) (see section 5.2).
Pri bolnikih z okvarjenim delovanjem ledvic (očistek kreatinina &gt; 4 ml/min) odmerka ni treba prilagajati (glejte poglavje 5.2).
No dose adjustment is necessary in patients with mild to moderate renal impairment, see section 4.4 for patients with severe renal impairment (eGFR &lt; 30 mL/min/1.73 m2).
Bolnikom z blago do zmerno okvaro ledvic odmerka ni treba prilagoditi, za bolnike s hudo okvaro ledvic (eGFR &lt; 30 ml/min/1,73 m2) glejte poglavje 4.4.
No dose adjustment is necessary in TIH patients with serum creatinine &lt; 400 micromol/l or &lt; 4.5 mg/dl (see section 4.4).
Bolnikom s TIH in serumskim kreatininom &lt; 400 mikromolov/l ali &lt; 4,5 mg/dl odmerka ni treba prilagoditi (glejte poglavje 4.4).
No dose adjustment is necessary in TIH patients with serum creatinine &lt; 400 µmol/l or &lt; 4.5 mg/dl (see section 4.4).
Pri bolnikih s tumorsko povzročeno hiperkalciemijo (TIH), s serumskim kreatininom &lt; 400 µmol/l ali &lt; 4,5 mg/dl, ni potrebno prilagajanje odmerjanja (glejte poglavje 4.4).
No dose adjustment is necessary in TIH patients with serum creatinine &lt; 400 µmol/l or &lt; 4.5 mg/dl (see section 4.4).
Pri bolnikih s tumorsko povzročeno hiperkalciemijo (TIH), s serumskim kreatininom &lt; 400 μmol/l ali &lt; 4,5 mg/dl, ni potrebno prilagajanje odmerjanja (glejte poglavje 4.4).
No dose adjustment is necessary in TIH patients with serum creatinine &lt; 400 μmol/l or &lt; 4.5 mg/dl (see section 4.4).
Pri bolnikih s tumorsko povzročeno hiperkalciemijo (TIH), s serumskim kreatininom &lt; 400 µmol/l ali &lt; 4,5 mg/dl, ni potrebno prilagajanje odmerjanja (glejte poglavje 4.4).
No dose adjustment is necessary in TIH patients with serum creatinine &lt; 400 μmol/l or &lt; 4.5 mg/dl (see section 4.4).
Pri bolnikih s tumorsko povzročeno hiperkalciemijo (TIH), s serumskim kreatininom &lt; 400 μmol/l ali &lt; 4,5 mg/dl, ni potrebno prilagajanje odmerjanja (glejte poglavje 4.4).
No dose adjustment is necessary in TIH patients with serum creatinine &lt; 400 μmol/l or &lt; 4.5 mg/dl (see section 4.4).
Pri bolnikih s tumorsko povzročeno hiperkalciemijo (TIH), z vrednostmi serumskega kreatinina &lt; 400 µmol/l ali &lt; 4,5 mg/dl, prilagajanje odmerjanja ni potrebno (glejte poglavje 4.4).
No dose adjustment is recommended for mild to moderate renal impairment (creatinine clearance &gt; 30 ml/min) (see section 5.2).
Pri blagi do zmerni okvari ledvic (očistek kreatinina &gt; 30 ml/min) odmerka ni treba prilagoditi (glejte poglavje 5.2).
No dose adjustment is recommended for mild to moderate renal impairment (creatinine clearance &gt; 30 ml/min).
Bolnikom z blago do zmerno okvaro ledvic (očistek kreatinina &gt; 30 ml/min) odmerka ni treba prilagoditi.
No dose adjustment is recommended in patients with mild hepatic impairment (total bilirubin ≤upper limit of normal (ULN) and aspartate aminotransferase (AST) &gt; ULN or total bilirubin &gt; 1.0 to 1.5x ULN and any AST) but caution should be used when administering TAGRISSO to these patients.
Bolnikom z blago okvaro jeter (celokupni bilirubin ≤ zgornja meja normalne vrednosti (ZMN) in aspartat aminotransferaza (AST) &gt; ZMN ali celokupni bilirubin &gt; od 1- do 1,5-kratne ZMN ne glede na AST) odmerka ni treba prilagoditi, vendar je treba zdravilo TAGRISSO pri teh bolnikih uporabljati previdno.
No dose adjustment is required in elderly patients (aged &gt; 65 years).
Starejšim bolnikom ( &gt; 65 let) odmerka ni treba prilagoditi.
No dose adjustment is required in patients with mild, moderate or severe hepatic impairment defined based on National Cancer Institute Organ Dysfunction Working Group (NCI-ODWG)- criteria for hepatic impairment: mild:total bilirubin (TB) ≤ upper limit of normal (ULN), aspartate aminotransferase (AST) &gt; ULN or ULN &lt; TB≤1.5xULN, AST any moderate: 1.5 x ULN &lt; TB &lt; 3 x ULN, AST any severe: 3 x ULN &lt; TB &lt; 10 x ULN, AST any (see section 5.2)
Odmerka ni treba prilagoditi bolnikom z blago, zmerno ali hudo jetrno okvaro glede na merila NCI- ODWG (National Cancer Institute Organ Dysfunction Working Group) za jetrno okvaro: blaga: celokupni bilirubin (CB) ≤ zgornja meja normale (ZMN), aspartat aminotransferaza (AST) &gt; ZMN ali ZMN &lt; CB ≤ 1,5 x ZMN, ne glede na AST, zmerna: 1,5 x ZMN &lt; CB &lt; 3 x ZMN, ne glede na AST, huda: 3 x ZMN &lt; CB &lt; 10 x ZMN, ne glede na AST (glejte poglavje 5.2).
No dose adjustment of Empliciti is required for patients with mild (CrCl = 60 - 89 mL/min), moderate (CrCl = 30 - 59 mL/min), severe (CrCl &lt; 30 mL/min) renal impairment or end stage renal disease requiring dialysis (see section 5.2).
Pri bolnikih z blago (CrCl = 60 - 89 ml/min), zmerno (CrCl = 30 - 59 ml/min), hudo (CrCl &lt; 30 ml/min) okvaro ledvic ali končno odpovedjo ledvic, ki potrebujejo zdravljenje z dializo, odmerka zdravila Empliciti ni treba prilagajati (glejte poglavje 5.2).
No dosing recommendations can be made for the very young (children &lt; 2 years of age) and Telzir with ritonavir is not recommended for this patient population (see section 4.2).
Za zelo mlade otroke (mlajše od 2 let) priporočil za odmerjanje ni in zdravilo Telzir v kombinaciji z ritonavirjem za to populacijo ni primerno (glejte poglavje 4.2).
No dosing recommendations can be made for the very young (children &lt; 2 years of age) and Telzir with ritonavir is not recommended for this patient population (see section 4.2).
Za zelo mlade otroke (mlajše od 2 let) priporočil za pdmerjanje ni in zdravilo Telzir v kombinaciji z ritonavirjem za to populacijo ni primerno (glejte poglavje 4.2).
No increase in the incidence of other reactions, including gastrointestinal perforation, wound healing complications, congestive heart failure, and haemorrhage was observed in elderly patients ( &gt; 65 years) receiving Avastin as compared to those aged ≤ 65 years treated with Avastin.
Pri starejših bolnikih ( &gt; 65 let), zdravljenih z zdravilom Avastin, v primerjavi z bolniki, starimi 65 let ali manj, zdravljenimi z zdravilom Avastin, ni bilo opaziti povečanja incidence drugih neželenih učinkov, vključno s perforacijami prebavil, zapleti pri celjenju ran, kongestivnim srčnim popuščanjem in krvavitvami.
No information on the use of ZYPADHERA in patients &gt; 75 years is available.
Na voljo ni podatkov o uporabi zdravila ZYPADHERA pri bolnikih starejših &gt; 75 let.
No initial dose adjustment is required in patients &gt; 65 years of age.
Bolnikom, starim &gt; 65 let, začetnega odmerka ni treba prilagoditi.
No overall differences in efficacy and safety of the combination of Tyverb and letrozole were observed between these patients and patients &lt; 65 years of age.
V celoti niso ugotovili razlik v učinkovitosti in varnosti kombinacije zdravila Tyverb in letrozola pri teh bolnikih v primerjavi z bolniki, mlajšimi od 65 let.
No overall differences in safety or effectiveness were observed between subjects over 65 years of age compared to younger adult ( &gt; 18 years of age) subjects receiving cytotoxic chemotherapy and clinical experience has not identified differences in the responses between elderly and younger adult patients.
Splošnih razlik v varnosti ali učinkovitosti pri osebah, starejših od 65 let, v primerjavi z mlajšimi odraslimi ( &gt; 18 let starosti) osebami, ki so prejemale citotoksično kemoterapijo, niso opazili, klinične izkušnje pa niso pokazale razlik v odzivu med starejšimi in mlajšimi odraslimi bolniki.
No overall differences in safety or effectiveness were observed between subjects over 65 years of age compared to younger adult ( &gt; 18 years of age) subjects receiving cytotoxic chemotherapy and clinical experience has not identified differences in the responses between elderly and younger adult patients.
V celoti niso opazili razlik v varnosti ali učinkovitosti med preiskovanci, starejšimi od 65 let, in mlajšimi odraslimi preiskovanci (starimi &gt; 18 let), ki so prejemali citotoksično kemoterapijo, klinične izkušnje pa niso pokazale razlik v odzivih med starejšimi in mlajšimi odraslimi bolniki.
No overall differences in safety or effectiveness were observed between women aged &gt; 65 years and younger women, but greater sensitivity of some older individuals cannot be ruled out.
Med ženskami, starimi &gt; 65 let in mlajšimi, na splošno niso opazili razlik v varnosti ali učinkovitosti, vendar večje občutljivosti nekaterih starejših žensk ni mogoče izključiti.
No overall differences in safety or efficacy have been observed in patients &lt; 65 and ≥ 65 years of age (see section 5.1).
Gledano v celoti se varnost in učinkovitost pri bolnikih, starih &lt; 65 in ≥ 65 let nista razlikovali (glejte poglavje 5.1).
No overall differences in safety or efficacy were observed between elderly (aged ≥ 65 years) and younger patients (aged &lt; 65 years) in the phase III study.
V klinični študiji III. faze niso opazili razlik v varnosti ali učinkovitosti med starejšimi (starimi ≥ 65 let) in mlajšimi bolniki (starimi &lt; 65 let).
No overall differences in safety or efficacy were reported between elderly ( ≥65 years) and younger patients ( &lt; 65 years).
O posebnih razlikah v varnosti in učinkovitosti med starostniki (≥ 65 let) in mlajšimi bolniki ( &lt; 65 let) niso poročali.
No overall differences in safety or efficacy were reported between elderly (≥ 65 years) and younger patients ( &lt; 65 years).
O posebnih razlikah v varnosti in učinkovitosti med starostniki (≥ 65 let) in mlajšimi bolniki ( &lt; 65 let) niso poročali.
No overall differences in safety or efficacy were reported between elderly (≥ 65 years) and younger patients ( &lt; 65 years).
O razlikah v varnosti in učinkovitosti med starostniki (≥ 65 let) in mlajšimi bolniki ( &lt; 65 let) niso poročali.
No overall differences in safety or efficacy were reported between elderly patients (≥ 65 years) and younger patients ( &lt; 65 years).
Na splošno niso ugotovili razlik v varnosti in učinkovitosti med starejšimi (≥ 65 let) in mlajšimi bolniki ( &lt; 65 let).
No overall differences in safety were reported between elderly (≥ 65 years) and younger patients ( &lt; 65 years).
O posebnih razlikah v varnosti med starostniki (≥ 65 let) in mlajšimi bolniki ( &lt; 65 let) niso poročali.
No patient had a QTcF &gt; 480 msec.
Interval QTcF pri nobenem od bolnikov ni bil daljši od 480 milisekund.
No patient had a QTcF value &gt; 500 ms.
Interval QTcF pri nobenem od bolnikov ni bil daljši od 500 ms.
No patient had an absolute QTcF &gt; 500 msec while on the study medicinal product.
Absolutno trajanje intervala QTcF v času jemanja študijskega zdravila pri nobenem od bolnikov ni bilo daljše od 500 milisekund.
No patient in either group developed a ΔQTc &gt; 60 msec.
Pri nobenem bolniku se ni niti v eni niti v drugi skupini pojavil ΔQTc &gt; 60 milisekund.
No patients in the crizotinib arm of randomised Phase 3 Studies 1007 and 1014, and single arm Study 1005 were &gt; 85 years.
Noben bolnik v skupini s krizotinibom v randomiziranih študijah 3. faze, Študiji 1007 in 1014, ter enoskupinski Študiji 1005 ni bil star  85 let.
No quantifiable levels ( &gt; 5 ng/ml) of drug were detected in serum after single or multiple topical doses.
Po enkratnem in večkratnem topičnem odmerku v serumu ni bilo zaznavnih koncentracij imikvimoda ( &gt; 5 ng/ml).
No reactivity or membranous reactivity in &lt; 10 % of tumour cells
Obarvanje ni prisotno ali pa je prisotno pri manj kot 10 % tumorskih celic.
No significant difference was observed in the PK of trastuzumab emtansine among patients &lt; 65 years (n = 577), patients between 65-75 years (n = 78) and patients &gt; 75 years (n = 16).
Farmakokinetika trastuzumaba emtanzina se ni bistveno razlikovala med bolniki, starimi &lt; 65 let (n = 577), bolniki, starimi od 65 do 75 let (n = 78), in bolniki, starimi &gt; 75 let (n = 16).
No significant differences in safety and efficacy of Perjeta were observed between elderly patients aged 65 to 75 years and adult patients aged &lt; 65 years.
Med odraslimi bolniki, starimi med 65 in 75 let, ter odraslimi bolniki, mlajšimi od 65 let, niso ugotovili pomembnih razlik v varnosti in učinkovitosti zdravila Perjeta.
No significant nausea (maximum VAS &lt; 25 mm on a scale of 0-100 mm)
Brez pomembne navzee (največja ocena &lt; 25 mm na vizualni analogni lestvici 0-100 mm)
No significant nausea (maximum VAS &lt; 25 mm on a scale of 0-100 mm)
Brez pomembne navzee (največja ocena &lt; 25 mm na vizualni analogni lestvici 0–100 mm)
No special dose adjustment is required in patients aged &gt; 65 years old.
Za bolnike, starejše od 65 let, prilagajanje odmerka ni potrebno.
No starting dose adjustment is recommended for patients with mild (60≤ creatinine clearance [CLcr] &lt; 90 mL/min) or moderate (30≤ CLcr &lt; 60 mL/min) renal impairment, since the population pharmacokinetic analysis indicated no clinically meaningful changes in steady-state crizotinib exposure in these patients.
Pri bolnikih z blago (60 ≤ očistek kreatinina [CLcr] &lt; 90 mL/min) ali zmerno (30 ≤ CLcr &lt; 60 mL/min) okvaro ledvic prilagajanje začetnega odmerka ni priporočeno, ker populacijska farmakokinetična analiza pri teh bolnikih ni pokazala klinično pomembnih sprememb v izpostavljenosti krizotinibu v stanju dinamičnega ravnovesja.
No subject had a QTcF &gt; 450 msec.
Pri nobenem od prostovoljcev trajanje QTcF ni preseglo 450 milisekund.
No teratogenic effects were observed in rabbits at &gt; 1,000 times human exposure.
Pri kuncih preko 1.000-krat večja izpostavljenost kot za človeka ni bila povezana s teratogenimi učinki.
No teratogenic effects were observed in rabbits at &gt; 1,000 times human exposure.
Pri kuncih več kot 1.000-krat večja izpostavljenost kot za človeka ni bila povezana s teragotenimi učinki.
Nodules are to be pre-treated at a light doses of 50 J/cm of diffuser length with a short ( &lt; 2.5 cm) fibre optic diffuser placed directly against the nodules followed by standard balloon application as described above.
50 J/cm dolžine difuzorja z difuzorjem s kratkimi ( &lt; 2,5 cm) optičnimi vlakni, nameščenim neposredno na vozličih, čemur sledi standardna uporaba balona, kot je opisano zgoraj.
Non species related breakpoints: S ≤ 0.5 mg/L and R &gt; 1 mg/L (NB: Susceptibility of staphylococci to ertapenem is inferred from the methicillin susceptibility)
Referenčne vrednosti ne glede na vrsto: S ≤ 0,5 mg/l in R &gt; 1 mg/l (Občutljivost stafilokokov na ertapenem se sklepa na osnovi občutljivosti na meticilin.)
Non species related S  1 mg/l and R &gt; 4 mg/l
Neodvisne od vrste S  1 mg/l in R &gt; 4 mg/l
Non-inferiority for the proportion of subjects achieving an IgG concentration 0.35 μg/ml was demonstrated for all 13 serotypes (lower bound of the 97.5% confidence interval (CI) for the difference in percentage of responders at 0.35 µg/ml between groups was &gt; -10%).
Enakovrednost za delež preskušancev, ki so dosegli koncentracijo IgG ≥ 0,35 µg/ml, je bila dokazana za vseh 13 serotipov (spodnja meja 97,5 % IZ za razliko v deležu preskušancev z odzivom 0,35 µg/ml med skupinami je bila &gt; -10 %).
Non-steroidal anti- inflammatory drugs (NSAIDs), including selective cyclooxygenase-2 inhibitors (COX-2 inhibitors), acetylsalicylic acid ( &gt; 3 g/day), and non- selective NSAIDs
nesteroidna protivnetna zdravila (NSAIDs), vključno s selektivnimi zaviralci ciklooksigenaze-2 (z zaviralci COX-2), acetilsalicilno kislino ( &gt; 3 g/dan) in neselektivnimi NSAIDs
Non-steroidal anti- inflammatory medicines (NSAIDs), including selective cyclooxygenase-2 inhibitors (COX-2 inhibitors), acetylsalicylic acid ( &gt; 3 g/day), and non- selective NSAIDs
nesteroidna protivnetna zdravila (NSAIDs), vključno s selektivnimi zaviralci ciklooksigenaze-2 (z zaviralci COX-2), acetilsalicilno kislino ( &gt; 3 g/dan) in neselektivnimi NSAIDs
Non-steroidal anti-inflammatory drugs (NSAIDs), including selective COX-2 inhibitors, acetylsalicylic acid &gt; 3 g/day), and non-selective NSAIDs
Nesteroidna protivnetna zdravila (NSAID), vključno s selektivnimi zaviralci COX-2, acetilsalicilno kislino ( &gt; 3 g/dan) in neselektivnimi NSAID
Non-steroidal anti-inflammatory drugs: when angiotensin II antagonists are administered simultaneously with non-steroidal anti- inflammatory drugs (i.e. selective COX-2 inhibitors, acetylsalicylic acid ( &gt; 3 g/day) and non-selective NSAIDs), attenuation of the antihypertensive effect may occur.
Nesteroidna protivnetna zdravila: pri sočasnem zdravljenju z antagonisti angiotenzina II in nesteroidnimi protivnetnimi zdravili (NSAID) (npr. selektivnimi COX-2 zaviralci, acetilsalicilno kislino ( &gt; 3 g/dan) in neselektivnimi NSAID) se lahko antihipertenzivni učinek zmanjša.
Non-steroidal anti-inflammatory drugs: when angiotensin II antagonists are administered simultaneously with non-steroidal anti-inflammatory drugs (i.e. selective COX-2 inhibitors, acetylsalicylic acid ( &gt; 3 g/day) and non-selective NSAIDs), attenuation of the antihypertensive effect may occur.
Nesteroidna protivnetna zdravila: kadar sočasno jemljemo antagoniste angiotenzina II in nesteroidna protivnetna zdravila (NSAID) (npr. selektivne COX-2 zaviralce, acetilsalicilno kislino ( &gt; 3 g dnevno) in neselektivne NSAID) lahko oslabi antihipertenzivni učinek.
Non-steroidal anti-inflammatory medicines (NSAIDs), including selective COX-2 inhibitors, acetylsalicylic acid ( &gt; 3 g/day), and non-selective NSAIDs
Nesteroidna protivnetna zdravila (NSAIDs), vključno s selektivnimi zaviralci COX-2, acetilsalicilno kislino ( &gt; 3 g/dan) in neselektivnimi NSAIDs
Nonafact contains trace amounts ( &lt; 0.1 ng mouse IgG/IU of factor IX) of the murine monoclonal antibody used in its purification.
Zdravilo Nonafact vsebuje monoklonska protitelesa glodalca v sledovih ( &lt; 0,1 ng mišjega IgG/i.e. faktorja IX), uporabljenih pri njegovem prečiščevanju.
None of the metabolites were present in &gt; 10% of the plasma concentrations of parent or total parent and metabolite related material.
Noben presnovek ni presegel &gt; 10 % plazemske koncentracije matične snovi ali celotne koncentracije matične spojine in s presnovki povezanih snovi.
Noninferior compared to enoxaparin/warfarin (p-value &lt; 0.0001)
enakovreden v primerjavi z enoksaparinom/varfarinom (vrednost p &lt; 0,0001)
Norelgestromin and norgestrel (a serum metabolite of norelgestromin) are highly bound ( &gt; 97%) to serum proteins.
Norelgestromin in norgestrel (serumski metabolit norelgestromina) se v veliki meri vežeta ( &gt; 97 %) na serumske proteine.
Normal individuals and heterozygous subjects for cystinosis have white cell cystine levels of &lt; 0.2, and usually below 1 nmol hemicystine/mg protein, respectively.
Pri normalnih osebah je koncentracija cistina v levkocitih &lt; 0,2, pri osebah, heterozigotnih za cistinozo, pa običajno nižja od 1 nmol hemicistina/mg beljakovin.
Normal individuals and heterozygous subjects for cystinosis have white cell cystine levels of &lt; 0.2, and usually below 1 nmol hemicystine/mg protein, respectively.
Pri normalnih osebah, je koncentracija cistina v levkocitih &lt; 0,2, pri osebah, heterozigotnih za cistinozo, pa običajno nižja od 1 nmol hemicistina/mg beljakovin.
Normal weight: BMI 18.5-25 kg/m2, Pre-adipose: BMI 25-30 kg/m2, Adipose: BMI &gt; 30 kg/m2, SD = Standard deviation
Normalna telesna masa: ITM 18,5–25 kg/m2, Predadipoznost: ITM 25–30 kg/m2, Debelost: ITM &gt; 30 kg/m2, SD = standardni odklon
Not reached (Range: &gt; 0.0 to &gt; 16.8 months)
Ni dosežen (Razpon: &gt; 0,0 do &gt; 16,8 mesecev)
Not statistically significant (p &gt; 0.05).
Ni statistično značilno (p &gt; 0,05).
Not statistically significant (p  0.05).
Ni statistično značilno (p &gt; 0,05).
Note that the intensity is higher ( &gt; 60% of max) in the grey matter regions of the positive images compared to the negative images and that the intensity radiates to a sharply defined convex edge in the lateral aspects.
Upoštevajte, da je intenziteta večja ( &gt; 60 % največje) v predelih sive možganovine na pozitivnih posnetkih v primerjavi z negativnimi posnetki, ter da se intenziteta širi z ostro določenim konveksnim robom v lateralnih legah.
Note: An OR &gt; 1 indicates an advantage for bortezomib-containing induction therapy
Opomba: OR &gt; 1 kaže na prednost uvajalnega zdravljenja z B.
Note: An OR &gt; 1 indicates an advantage for bortezomib-containing induction therapy.
Opomba: OR &gt; 1 kaže na prednost uvajalnega zdravljenja z Bz.
Note: An OR &gt; 1 indicates an advantage for Bz-containing induction therapy
Opomba: OR &gt; 1 kaže na prednost uvajalnega zdravljenja z Bz.
Note: An OR &gt; 1 indicates an advantage for Bz-containing induction therapy.
Opomba: OR &gt; 1 kaže na prednost uvajalnega zdravljenja z Bz.
Note: An OR &gt; 1 indicates an advantage for Bzmb-containing induction therapy
Opomba: OR &gt; 1 kaže na prednost uvajalnega zdravljenja z Bzmb.
Note: An OR &gt; 1 indicates an advantage for Bzmb-containing induction therapy.
Opomba: OR &gt; 1 kaže na prednost uvajalnega zdravljenja z Bzmb.
Note: An OR &gt; 1 indicates an advantage for Vc-containing induction therapy
Opomba: OR &gt; 1 kaže na prednost uvajalnega zdravljenja z Vc.
Note: An OR &gt; 1 indicates an advantage for Vc-containing induction therapy.
Opomba: OR &gt; 1 kaže na prednost uvajalnega zdravljenja z Vc.
Note: Based on a population pharmacokinetic analysis in 112 immunocompromised paediatric patients aged 2 to &lt; 12 years and 26 immunocompromised adolescents aged 12 to &lt; 17 years.
Opomba: Na podlagi populacijske farmakokinetične analize pri 112 imunsko oslabelih otrocih, starih od 2 do &lt; 12 let, in 26 imunsko oslabelih mladostnikih, starih od 12 do &lt; 17 let.
Note: For patients who weigh &lt; 47 kg, or are unable to swallow capsules, ribavirin oral solution is available and should be used if appropriate.
Opomba: Za bolnike, ki tehtajo &lt; 47 kg ali ne morejo pogoltniti kapsule, je na voljo peroralna raztopina ribavirina.